secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001140361-24-017807
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut
--------------------------------------------------------------------------------

- Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
- Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.
- Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).
- Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.
- FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/ef20026031_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-017807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer